Libervant in Saudi Arabia
How patients in Saudi Arabia access Libervant (diazepam buccal film) via Named Patient Program.
Libervant - overview
Libervant (diazepam buccal film) is manufactured by Aquestive Therapeutics and indicated for Seizure clusters — OUT OF SCOPE (DEA Schedule IV; PlatformCo does not handle controlled substances. Fatima's DEA-registered entity may pursue separately.). It is a unverified approved by the US FDA in unverified and may be accessible to patients in Saudi Arabia through a Named Patient Program or personal-import pathway.
Access in Saudi Arabia
The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
How Reserve Meds coordinates access in Saudi Arabia
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Saudi Arabia-specific eligibility.
- Treating physician in Saudi Arabia issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Libervant from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Saudi Arabia.
Typical timeline for Saudi Arabia
End-to-end, most requests are completed in 2-6 weeks. Saudi Arabia's tier 1 regulatory maturity typically supports fast processing times.
What patients and physicians in Saudi Arabia ask
- Is the pathway legal in Saudi Arabia? Yes - it operates under Saudi Arabia's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Saudi Arabia able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.